Ongoing monitoring to sustain remission and manage recovery.
Autologous, allogeneic, and haploidentical transplants for blood cancers and marrow failure.
Modern drugs that target cancer cells precisely while sparing healthy tissue.
Next-generation cell therapy for eligible myeloma and lymphoma patients.